pI: 5.2157 |
Length (AA): 429 |
MW (Da): 50151 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 8 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
217 | 428 | 1nf9 (A) | 7 | 206 | 10.00 | 0 | 0.26 | 0.59 | -0.56 |
246 | 422 | 1im5 (A) | 5 | 178 | 27.00 | 0 | 1 | 0.74 | -0.4 |
28 | 88 | 2jbx (A) | 9 | 66 | 40.00 | 0.65 | 0.04 | 0.256891 | 1.24 |
232 | 429 | 3r2j (A) | 22 | 213 | 19.00 | 0.0000000000055 | 1 | 0.659038 | 0.25 |
28 | 88 | 2jbx (A) | 9 | 66 | 40.00 | 0.88 | 0.05 | 0.237691 | 1.43 |
232 | 429 | 3r2j (A) | 22 | 213 | 22.00 | 0 | 1 | 0.700838 | 0.15 |
335 | 427 | 4wgf (A) | 74 | 168 | 18.00 | 0.018 | 0.98 | 0.526083 | -0.57 |
367 | 428 | 2b34 (A) | 102 | 165 | 23.00 | 0.17 | 0.33 | 0.379822 | -0.08 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 16 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, Sporozoite. | Otto TD Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 8 hs, intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, merozoite, early schizont, early trophozoite, late schizont, late trophozoite, Female Gametocyte. | Otto TD PlasmoDB Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Oocyst, Ring, Male Gametocyte. | Zanghi G Lasonder E |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_127752)
Species | Accession | Gene Product |
---|---|---|
Candida albicans | CaO19.14000 | pyrazinamidase/nicotinamidase |
Candida albicans | CaO19_6684 | hypothetical protein |
Candida albicans | CaO19.6684 | pyrazinamidase/nicotinamidase |
Candida albicans | CaO19.6708 | pyrazinamidase/nicotinamidase |
Candida albicans | CaO19.13976 | pyrazinamidase/nicotinamidase |
Caenorhabditis elegans | CELE_Y38C1AA.3 | Protein PNC-1, isoform B |
Caenorhabditis elegans | CELE_Y57G11C.47 | Protein PNC-2 |
Dictyostelium discoideum | DDB_G0293618 | hypothetical protein |
Dictyostelium discoideum | DDB_G0271336 | hypothetical protein |
Drosophila melanogaster | Dmel_CG31216 | Nicotinamide amidase |
Escherichia coli | b1768 | nicotinamidase/pyrazinamidase |
Giardia lamblia | GL50803_6757 | Pyrazinamidase/nicotinamidase |
Leishmania braziliensis | LbrM.01.0500 | alpha/beta-hydrolase-like protein |
Leishmania donovani | LdBPK_010470.1 | alpha/beta-hydrolase-like protein |
Leishmania infantum | LinJ.01.0470 | alpha/beta-hydrolase-like protein |
Leishmania major | LmjF.01.0450 | alpha/beta-hydrolase-like protein |
Leishmania mexicana | LmxM.01.0450 | alpha/beta-hydrolase-like protein |
Mycobacterium tuberculosis | Rv2043c | Pyrazinamidase/nicotinamidase PncA (PZase) |
Mycobacterium ulcerans | MUL_2257 | pyrazinamidase/nicotinamidase, PncA |
Neospora caninum | NCLIV_023670 | pyrazinamidase/nicotinamidase, putative |
Plasmodium berghei | PBANKA_1218000 | nicotinamidase, putative |
Plasmodium falciparum | PF3D7_0320500 | nicotinamidase, putative |
Plasmodium knowlesi | PKNH_0820300 | nicotinamidase, putative |
Plasmodium vivax | PVX_095210 | nicotinamidase, putative |
Plasmodium yoelii | PY05269 | isochorismatase family protein, putative |
Saccharomyces cerevisiae | YGL037C | nicotinamidase |
Schmidtea mediterranea | mk4.062833.00 | |
Trypanosoma brucei gambiense | Tbg972.9.2100 | pyrazinamidase/nicotinamidase, putative |
Trypanosoma brucei | Tb927.9.4040 | nicotinamidase, putative |
Trypanosoma brucei | Tb927.9.3970 | nicotinamidase, putative |
Trypanosoma congolense | TcIL3000_0_18470 | nicotinamidase, putative |
Trypanosoma cruzi | TcCLB.506593.60 | nicotinamidase, putative |
Trypanosoma cruzi | TcCLB.506829.80 | nicotinamidase, putative |
Toxoplasma gondii | TGME49_281990 | Nicotinamidase |
Trichomonas vaginalis | TVAG_366320 | pyrazinamidase/nicotinamidase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu2075 | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb09.160.2540 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.2540 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.2540 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.160.2540 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b1768 | Escherichia coli | non-essential | goodall |
PBANKA_1218000 | Plasmodium berghei | Dispensable | plasmo |
TGME49_281990 | Toxoplasma gondii | Probably non-essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.